Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27142446 | 1.00 | ABL1 (1.00) | ABL1CSF1R | |
| SCHEMBL30011189 | 0.92 | ABL1 (1.00) | ABL1 | |
| SCHEMBL16644581 | 0.92 | ABL1 (1.00) | ABL1 | |
| SCHEMBL30788443 | 0.91 | ABL1 (0.88) | ABL1CSF1R | |
| SCHEMBL30788435 | 0.91 | ABL1 (0.88) | ABL1CSF1R | |
| SCHEMBL16644553 | 0.91 | ABL1 (0.83) | ABL1CSF1R | |
| SCHEMBL24123283 | 0.89 | ABL1 (1.00) | ABL1 | |
| SCHEMBL30011095 | 0.89 | ABL1 (1.00) | ABL1 | |
| SCHEMBL30010951 | 0.89 | ABL1 (1.00) | ABL1CSF1R | |
| SCHEMBL27142472 | 0.89 | ABL1 (1.00) | ABL1CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199626-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4326269-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | Oregon Health & Science University (US) | 2024-02-28 | — | — | EP | disclosed |
| WO-2022225972-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2022-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199626-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | SMN1; SMN2, MCL1, NLN | ABL1 76/4885CSF1R 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.